Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bacteria and other microorganisms of the intestinal tract (collectively known as the gut microbiota) have fundamental roles in maintaining a healthy immune system. The ultimate goal of the Inflammatory Arthritis Microbiome Consortium (IAMC) is to manipulate the human microbiota for the treatment of inflammatory arthritis.

The IAMC team


We are an international consortium of world leading scientists from a number of complementary disciplines. Our extensive clinical, immunological, computational and microbiological expertise place us in a unique position to perform in-depth analysis of the role of the microbiome in inflammatory arthritis (IA) and how the manipulation of bacterial communities may present a novel therapeutic for this set of diseases.

The consortium utilises state-of-the-art technologies in DNA and RNA sequencing as well as metabolomics (the process of identifying the products of metabolism) to characterise microbial community structure and function in relation to arthritis. This will identify specific host-microbiota interactions that are important in disease development, progression and response to therapy which may provide novel avenues for the development of therapeutics in the future.


Image showing in situ microbial profiling and the effects it has in vitro on the immune system; and in vivo on pathology and immunity


The collaborative research of the IAMC is made possible through a Strategic Award from Versus Arthritis, as well through funding from the Kennedy Trust for Rheumatology Research (KTRR) and the Colton Center for the Study of Autoimmunity at the NYU School of Medicine.


The study began in April 2016 and is currently split into two working groups; Ankylosing Spondylitis (AS) and Rheumatoid Arthritis (RA).

Ankylosing Spondylitis (AS) – This group is addressing whether specific microbes and/or their metabolites can be correlated to the inflammatory symptoms of AS. The group are searching for microbial biomarkers by collecting stool samples from AS patients and controls in Oxford. The study team will also be isolating key microbes and assessing the mode in which they interact with specific aspects of the immune system in a variety of experimental models.

Rheumatoid Arthritis (RA) – The initial work here focuses on early undifferentiated RA with samples collected at first point of contact with the medical team based in Birmingham. Stool samples are analysed for their microbial communities which are then correlated with the eventual patient outcome. It is hoped that this work will highlight any links between microbial content and patient disease outcome.

Response to Therapy – Work also to be completed by the RA working group includes characterisation of the gut microbiome and its correlation to how patients respond to therapy. There is a broad spectrum of drug treatments and combination treatments for RA and our team will be analysing how many of them interact with the gut microbiome and how this interaction affects how patients react to different drugs. In the future it is hoped that information from this study will help guide future drug development and examine the use of microbiota as a therapeutic.

Juvenile Idiopathic Arthritis (JIA) – JIA patients that present during childhood, are entered into our studies via clinics at Great Ormond Street Hospital and UCLH. Samples from these cohorts will feed into the RA and AS working groups and the differences between microbiota from adult onset and juvenile onset arthritides examined. 


1. To determine whether the gut microbiome of patients with RA, AS and the juvenile forms of these diseases is abnormal.

2. To show how microbiome biomarkers can predict disease outcomes and response to therapy.

3. To elucidate how specific microbes or their components may cause, enhance or protect against disease.


Powrie-smallProfessor Fiona Powrie FRS 

Professor of Musculoskeletal Sciences and Director of the Kennedy Institute of Rheumatology, University of Oxford


Bowness-smallProfessor Paul Bowness

Professor of Experimental Rheumatology, Oxford Botnar Research Centre, University of Oxford and Consultant Rheumatologist, OUH NHS trust, Oxford


Faith-smallDr Jeremiah Faith

Assistant Professor, Immunology Institute and Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai


HuttenhowerProfessor Curtis Huttenhower

Associate Member, Broad Institute of MIT and Harvard School of Public Health



CozianaCiurtinsmall.pngDr Coziana Ciurtin

Clinical Senior Lecturer /Honorary Consultant Adolescent Rheumatology



Littman-smallProfessor Dan Littman

Helen L. and Martin S. Kimmel Professor of Molecular Immunology, New York University School of Medicine




Professor Claudia Mauri

Professor of Immunology, Centre for Rheumatology research, University College London 



Raza-smallProfessor Karim Raza

Professor of Clinical Rheumatology, University of Birmingham 



Taylor-smallProfessor Peter Taylor

Norman Collisson Professor of Musculoskeletal Sciences, Kennedy Institute of Rheumatology & Oxford Botnar Research Centre, University of Oxford


Wedderburn-smallProfessor Lucy Wedderburn

Professor of Paediatric Rheumatology and Director Arthritis Research UK Centre for Adolescent Rheumatology, University College London 


Young-smallDr Stephen Young

Reader in Experimental Rheumatology, University of Birmingham



PaulaColmenerosmall.pngDr Paula Colmenero

Scientific Project Manager